Ataxia Telangiectasia Associated with B-Cell Lymphoma: The Effect of a Half-Dose of the Drugs Administered According to the Acute Lymphoblastic Leukemia Standard Risk Protocol

Yukiji Yamada Department of Pediatrics, Gifu University, School of Medicine, Gifu, Japan

Ryosuke Inoue Department of Pediatrics, Gifu University, School of Medicine, Gifu, Japan

Toshiyuki Fukao Department of Pediatrics, Gifu University, School of Medicine, Gifu, Japan

Hideo Kaneko Department of Pediatrics, Gifu University, School of Medicine, Gifu, Japan

Kouji Isogai Department of Pediatrics, Gifu University, School of Medicine, Gifu, Japan

Seiji Fukuda Department of Pediatrics, Gifu University, School of Medicine, Gifu, Japan

Nobuyuki Shimozawa Department of Pediatrics, Gifu University, School of Medicine, Gifu, Japan

Yasuyuki Suzuki Department of Pediatrics, Gifu University, School of Medicine, Gifu, Japan

Naomi Kondo Department of Pediatrics, Gifu University, School of Medicine, Gifu, Japan

Eichi Azuma Department of Pediatrics and Clinical Immunology, Mie University, School of Medicine, Tsu, Mie, Japan

Minoru Sakurai Department of Pediatrics and Clinical Immunology, Mie University, School of Medicine, Tsu, Mie, Japan

show all

Abstract

Ataxia telangiectasia (A-T) is a rare autosomal recessive disorder characterized by cerebellar ataxia, oculocutaneous telangiectasia, and variable degrees of humoral and cellular immunodeficiency. Affected individuals are known to exhibit a high incidence of lymphoma and leukemia. Because of increased chemosensitivity, the treatment of A-T patients with malignancies requires extremely careful planning and caution with respect to the use of chemotherapy. The authors report on a 12-year-old boy with A-T who developed B-cell lymphoma. He received a half-dose of the drugs administered according to the acute lymphoblastic leukemia (ALL) protocol issued by our children's cancer study group (9104 Standard Risk Protocol, Tokai Pediatric Oncology Study Group). As a result, he continues to be in complete remission and free of treatment complications 32 months after the diagnosis of B-cell lymphoma.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Ataxia Telangiectasia Associated with B-Cell Lymphoma: The Effect of a Half-Dose of the Drugs Administered According to the Acute Lymphoblastic Leukemia Standard Risk Protocol

Information for

Open access

Opportunities

Help and information

Ataxia Telangiectasia Associated with B-Cell Lymphoma: The Effect of a Half-Dose of the Drugs Administered According to the Acute Lymphoblastic Leukemia Standard Risk Protocol

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature